Recently, following KEYNOTE-811, the FDA and European Medicines Agency (EMA) granted accelerated approval for the therapeutic combination of pembrolizumab and trastuzumab in patients bearing HER2-positive and PD-L1 CPS ≥ 1 GA/GEJA, who had not received prior systemic chemotherapy for metastatic disease [18,19]. Here, CD274 is linked to metastatic neoplasm.